The Usefulness of Serum Vitamin D Levels in the Assessment of IBD Activity and Response to Biologics.
Crohn’s disease
biological therapy
inflammatory bowel disease
ulcerative colitis
vitamin D
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
22 Jan 2021
22 Jan 2021
Historique:
received:
13
12
2020
revised:
17
01
2021
accepted:
20
01
2021
entrez:
27
1
2021
pubmed:
28
1
2021
medline:
10
9
2021
Statut:
epublish
Résumé
The main role of vitamin D is calcium homeostasis and bone metabolism, although its activity as an immuno-modulator and its anti-inflammatory effect is well-known. Low blood vitamin D levels are common among patients with inflammatory bowel disease (IBD). Whether low vitamin D levels could affect the disease activity or it is an effect of a worse condition of the disease is still unclear. This study aimed to investigate the role of blood vitamin D levels to identify the clinical, endoscopic, and histological activity in a cohort of patients with ulcerative colitis (UC) or Crohn's disease (CD) on therapy with biological drugs. In this retrospective cohort study, 50 IBD patients (24 UC and 26 CD) that underwent colonoscopy from January 2017 to January 2020 with a concomitant serological evaluation of vitamin D were included. Patients with clinical, endoscopic, and histological activity and those who lost their clinical response to the biological drug had lower vitamin D levels compared to patients in remission or patients that did not change therapeutic regimens. A receiver operating characteristic (ROC) analysis and Youden's Index were performed to assess the optimal vitamin D levels to identify patients with the active disease. The ROC analysis showed an area under the curve (AUC) of 0.709 (
Identifiants
pubmed: 33499406
pii: nu13020323
doi: 10.3390/nu13020323
pmc: PMC7910959
pii:
doi:
Substances chimiques
Biological Products
0
Biomarkers
0
Vitamin D
1406-16-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Aliment Pharmacol Ther. 2014 Jan;39(2):125-36
pubmed: 24236989
Aliment Pharmacol Ther. 2010 Aug;32(3):377-83
pubmed: 20491740
Crit Rev Biochem Mol Biol. 2019 Apr;54(2):184-192
pubmed: 31084433
Inflamm Bowel Dis. 2017 Dec 19;24(1):78-92
pubmed: 29272479
Inflamm Bowel Dis. 2015 Nov;21(11):2708-17
pubmed: 26348447
Med J Malaysia. 2013;68(1):34-8
pubmed: 23466764
Am J Physiol Renal Physiol. 2005 Jul;289(1):F8-28
pubmed: 15951480
J Crohns Colitis. 2019 Mar 26;13(3):273-284
pubmed: 30137278
J Gastroenterol Hepatol. 2020 Mar;35(3):390-400
pubmed: 31795013
JPEN J Parenter Enteral Nutr. 2014 Mar-Apr;38(3):385-91
pubmed: 24088707
Lancet. 2012 Nov 3;380(9853):1590-605
pubmed: 22914295
Gut. 2009 Apr;58(4):492-500
pubmed: 18832518
J Crohns Colitis. 2017 Jun 1;11(6):649-670
pubmed: 28158501
World J Gastroenterol. 2014 Jan 7;20(1):91-9
pubmed: 24415861
Nutrients. 2019 May 11;11(5):
pubmed: 31083541
J Crohns Colitis. 2010 Oct;4(4):355-66
pubmed: 21122530
Gastroenterology. 2012 Mar;142(3):482-9
pubmed: 22155183
Clin Gastroenterol Hepatol. 2017 Feb;15(2):240-246.e1
pubmed: 27266980
Am J Gastroenterol. 2016 May;111(5):712-9
pubmed: 26952579
Lancet. 2012 Nov 3;380(9853):1606-19
pubmed: 22914296
J Crohns Colitis. 2019 Feb 1;13(2):144-164
pubmed: 30137275
Nutrients. 2018 Nov 03;10(11):
pubmed: 30400332
J Crohns Colitis. 2018 May 25;12(6):742-752
pubmed: 29529167
J Crohns Colitis. 2014 Dec;8(12):1582-97
pubmed: 25267173
Clin Nutr. 2013 Dec;32(6):904-10
pubmed: 23602613
Aliment Pharmacol Ther. 2019 Dec;50(11-12):1146-1158
pubmed: 31647134
Curr Opin Gastroenterol. 2018 Jul;34(4):217-225
pubmed: 29762159
Gut. 1997 Feb;40(2):228-33
pubmed: 9071937